Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of concomitant radiotherapy with cisplatin versus radiotherapy alone in sinonasal and salivary gland tumors
2016-001816-39Phase 3Active
- Sponsor
- GORTEC
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cisplatin in head and neck squamous cell carcinoma (HNSCC), sinonasal carcinoma and salivary gland cancer (SGC) (2 arms), sponsored by GORTEC. Primary endpoint: Progression-free survival. Started Oct 2016; status: active.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)sinonasal carcinomasalivary gland cancer (SGC)
Beyond the preview
Go deeper on 2016-001816-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001816-39.